(Total Views: 393)
Posted On: 07/22/2018 3:48:53 AM
Post# of 72447
I agree that non-retail won’t be able to reset the 52-week again with three major catalysts approaching. Pre-revenue biotechs are mainly news-driven. Trading actions in July were less volatile so far due to impending news/result.
Non-retail was very fortunate to have Aspire’s 47M shares and major catalysts such as P result to be pushed back from Q1 to Q2 to Q3. Some investors became impatient and sold with the intention to buy back later. I’ve been in biotechs for decades and seen this pattern many times.
With Aspire and investors appear to be holding for news/result, there’s not much non-retail can do at this point. When Leo announces a licensing deal, checkmate!
Non-retail was very fortunate to have Aspire’s 47M shares and major catalysts such as P result to be pushed back from Q1 to Q2 to Q3. Some investors became impatient and sold with the intention to buy back later. I’ve been in biotechs for decades and seen this pattern many times.
With Aspire and investors appear to be holding for news/result, there’s not much non-retail can do at this point. When Leo announces a licensing deal, checkmate!
(3)
(0)
